Tag Archives: conflicts of interest

Disordering Normal—Here comes the new DSM

Towards the end of May, the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), the iconic bible of psychiatry, is coming off the presses after much revision and delay. It’s bound to keep people asking, “Am I normal or do I have a mental illness?”

If you think most diseases are established with objective criteria and rigorous debate, you’d be somewhat wrong. The DSM has a strong track record of taking clusters of symptoms and wrapping labels around them, which lead to the accelerated use of some of the most toxic medications on the planet. How does this happen?

ABC News: DSM-5 Criticized for Financial Conflicts of Interest—70% of task force members have ties to Pharma

Controversy continues to swell around the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, better known as DSM-5. A new study suggests the 900-page bible of mental health, scheduled for publication in May 2013, is ripe with financial conflicts of interest.

The manual, published by the American Psychiatric Association, details the diagnostic criteria and recommended treatments — many of which are pharmacological — for each and every psychiatric disorder. After the 1994 release of DSM-4, the APA instituted a policy requiring expert advisors to disclose drug industry ties. But the move toward transparency did little to cut down on conflicts, with nearly 70 percent of DSM-5 task force members reporting financial relationships with pharmaceutical companies — up from 57 percent for DSM-4.

Grassley & Senate Watchdog Target Doctors Prescribing Mass Amounts of Dangerous Drugs

An influential U.S. senator is grilling officials in nearly three-dozen states, demanding to know how they are cracking down on physicians who prescribe massive amounts of potentially dangerous prescription drugs.

Iowa Republican Charles Grassley sent letters to 34 states Monday asking what steps they had taken to investigate doctors whose prescribing of antipsychotics, anti-anxiety drugs and painkillers to Medicaid patients far exceeds that of their peers.

U.S. to Force Drug Firms to Report Money Paid to Doctors

Manufacturers of prescription drugs and devices will have to report if they pay a doctor to help develop, assess and promote new products — or if, for example, a pharmaceutical sales agent delivers $25 worth of bagels and coffee to a doctor’s office for a meeting. Royalty payments to doctors, for inventions or discoveries, and payments to teaching hospitals for research or other activities will also have to be reported.

The new standards carry out legislation championed by Senators Charles E. Grassley, Republican of Iowa, and Herb Kohl, Democrat of Wisconsin. The legislation was included in the 2010 health care overhaul.

“The goal is to let the sun shine in and make information available to foster accountability,” Mr. Grassley said.

NY Times—Payments to Doctors by Pharma Raise Issues of Conflicts, CCHR warns of tainted mental health policies

The financial relationships raise questions about the influence of drug companies on prescribing patterns or research results. The practice “puts patients and tax dollars at risk,” said Lee Spiller, the policy director for the Texas branch of the Citizens Commission on Human Rights, a nonprofit mental health watchdog. “It taints the whole process. I’d hate to think donations were shaping state mental health policy in particular.”